Posts Tagged ‘Allergy’

Ocular Therapeutix Waiting for Word from FDA

Ocular Therapeutix expects to hear from the FDA on its PDUFA date of July 24, 2016, on its new drug application for DEXTENZA, its sustained-release dexamethasone intracanalicular depot drug product candidate for treatment of postoperative pain, President and CEO Amar Sawhney, PhD, told the audience at OIS@ASCRS during the Ophthalmology Innovation Showcase. DEXTENZA would be…

Read More

TearScience Pivots to Focus on Early-Stage OSD

TearScience, the device company focused on the role of the meibomian glands in dry eye, has pivoted its business model to concentrate more on early-stage meibomian gland dysfunction (MGD) with the LipiFlow thermal pulsation device and high-definition imaging of the meibomian glands, President and CEO Joseph Boorady, OD, told OIS@ASCRS 2016. Dr. Boorady himself is…

Read More

How Eyenovia Aims to Solve the Problem of Eyedroppers

The natural solution to the problems associated with delivering drops to the front of the eye is inkjet printing, Eyenovia director Curt LaBelle, MD, told the “What’s the Future?” session at OIS@ASCRS 2016 in describing his company’s proprietary drug delivery device. The device looks like a small, white upright torpedo with a button and an…

Read More

Ocular Therapeutix Taking Aim at Allergy Market

Ocular Therapeutix Taking Aim at Allergy Market

Amar Sawhney, PhD, Chairman, Chairman, President & CEO of Ocular Therapeutics, touts the performance of Dextenza, the company’s anti-allergy medication. Instead of taking one drop a day, allergy sufferers just need one treatmet of Dextenza to survive a whole season. Speaking With: Amar Sawhney, PhD Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006, has since…

Read More

Oculeve’s Ackermann Talks Allergan

Oculeve’s Ackerman Talks Allergan

Michael Ackermann, CEO of start-up Oculeve, gives an update on his work with Allergan following the purchase of his company and its Dry Eye device. Ackermann explains how he’s fitting into Allergan’s folds and when we might expect to see Oculeve’s neurostimulation device. Speaking With: Michael Ackermann, PhD Michael is currently Vice President, Neurostimulation for…

Read More

Eleven Biotherapeutics

Eleven Biotherapeutics

Eleven Biotherapeutics is using its proprietary AMP-Rx protein-engineering platform to develop agents for more effective treatment of allergic conjunctivitis as well as to investigate new treatments for patients with diabetic macular edema (DME) who do not respond to anti-VEGF therapy. In October, the company had completed enrollment in its double-masked, randomized, vehicle-controlled Phase III pivotal…

Read More

ForSight VISION5

ForSight VISION5

The company is addressing non-adherence to eyedrops in glaucoma and in ocular hypertension. There remains a true, unmet need to provide clinically relevant intraocular pressure (IOP) reduction with a simple non-invasive product for patients who do not or cannot take their medications. ForSIGHT has developed Helios, a soft, preservative-free ring infused with bimataprost that is…

Read More

ForSight VISION5

ForSight VISION5 ASCRS 2015

Dedicated to solving compliance problems with ophthalmic medications, ForSight VISION5 has developed Helios, a non-invasive, sustained-release drug delivery system that remains in place for 6 months. Final data from a phase 2 study is expected by the end of the year, with plans in place for a phase 3 study in Q1 2016, and a…

Read More

Ocular Therapeutix

Ocular Therapeutix ASCRS 2015

The company is evaluating sustained-release injectable anti-VEGF drug depots along with using its proprietary hydrogel platform technology for anterior segment disorders (specifically pain and inflammation). The company’s OTX drug-eluting punctal plug is a non-invasive procedure that will eliminate drops (and the potential non-compliance). Two phase 3 studies have been completed on inflammation, with 39.4% absence…

Read More

Eleven Biotherapeutics

Eleven Biotherapeutics ASCRS 2015

Presenter: Abbie C. Celniker, PhD Dr. Celniker brings more than 20 years of proven protein therapeutic expertise to Eleven Biotherapeutics. Prior to joining Eleven, Abbie was CEO of Taligen Therapeutics, which was acquired by Alexion Pharmaceuticals. View Full Profile

Read More

ForSight VISION5

ForSight VISION5

ForSight VISION5 Inc. CEO John Maroney discussed his company’s novel, non-invasive insert system, Helios. Placed on the surface of the eye, under the eyelid, Helios enables glaucoma and ocular hypertensive patients to continually receive medication (such as “the drug of choice” prostaglandin A), eliminating their need to regularly administer eye drops. Results from a Phase…

Read More

TearScience

TearScience AAO 2014

TearScience Inc. CEO and Co-Founder Tim Willis emphasized that his company was founded for a single reason: to be the evaporative dry eye expert, and to develop a system to identify, diagnose, and treat Meibomian Gland Dysfunction, the root cause behind 90% of dry eye cases. He introduced for the first time TearScience’s LipiView II.…

Read More